Agilent receives FDA approval for breast cancer assay

By staff writers

October 14, 2021 -- Agilent Technologies has received approval from the U.S. Food and Drug Administration (FDA) for its Ki-67 IHC MIB-1 pharmDx assay. The assay can help identify patients with early breast cancer who are at high risk of disease recurrence.

The assay is intended for use in patients for whom adjuvant treatment with Verzenio (abemaciclib), in combination with endocrine therapy, is being considered. It is the first IHC assay measuring Ki-67 expression to receive FDA approval in conjunction with the treatment of Verzenio and was developed in collaboration with Eli Lilly and Company, Agilent said.

The approval builds on Agilent's previous successes in expanding the clinical applicability of therapeutic biomarker analysis and advances its position as a provider of diagnostic assays that deliver quality and ease of implementation, the company said.

Agilent enters digital pathology with Visiopharm deal
Agilent Technologies and Visiopharm have signed a worldwide distribution agreement that allows Agilent to co-market Visiopharm's portfolio of digital...
Agilent secures expanded CE Mark for cancer assay
Agilent Technologies has received an expanded CE Mark that will allow its PD-L1 IHC 22C3 pharmDx assay -- a companion diagnostic for the Keytruda chemotherapy...
Agilent launches SARS-CoV-2 antibody immunoassay kit
Agilent Technologies has launched a new immunoassay kit for the detection of SARS-CoV-2 antibodies. The kit represents Agilent's entry into the U.S. SARS-CoV-2...
Agilent updates Visiopharm image analysis software
Agilent Technologies has released an updated version of its Visiopharm image analysis software. The software now incorporates HercepTest monoclonal antibody...

Copyright © 2021

Last Updated ka 10/14/2021 5:18:34 PM